4
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0000899243-23-009182
Co-Chief Executive Officer sold 100,000 shares at an average $31.86 ($3,186,236)
- Co-Chief Executive Officer acquired 50,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Klee Justin B. Co-Chief Executive Officer | 2023-03-16 | Sale | −96,555 | $31.84 | $3,074,359 | 2,796,062 | D |
| Klee Justin B. Co-Chief Executive Officer | 2023-03-16 | Sale | −3,445 | $32.48 | $111,877 | 2,792,617 | D |
| Klee Justin B. Co-Chief Executive Officer | 2023-03-16 | Grant or award | +50,000 | 2,842,617 | D | ||
| Derivatives | |||||||
| Klee Justin B. Co-Chief Executive Officer | 2023-03-16 | Grant or award · Stock Option (right to buy) | +225,000 | 225,000 | D | ||
| Open-market sales · 100,000 sh · avg $31.86 · $3,186,236 | |||||||
Loading xslF345X04/doc4.xml…